review glp-1 receptor agonists show promise in treating substance use disorders Beyond GLP-1: Review of Next-Generation

"Not for a company to say: 'Oh, this is how I know we're going to make money

They have a BMI of 32, they can do everything they want, they're muscular, and you're saying I have a disease of obesity

10.1016/j.clinthera.2007.01.015 58

Some clinical trials suggest combination therapy with both SGLT2 inhibitors and GLP-1 agonists may provide up to 27% total weight loss, though this approach requires careful medical supervision

evaluated the effect of semaglutide in a 52-week randomized, double-blinded, placebo-controlled trial involving adults with increased fracture risk

Asian and South Asian populations in particular show cardiometabolic risk at lower BMI thresholds some guidelines use BMI 25+ as obesity for these populations